|
|||||
|
|
Erratum to: Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium |
|
| Authors: | Deborah A. Bradley Stephanie Daignault Charles J. Ryan Robert S. DiPaola Kathleen A. Cooney David C. Smith Eric Small Paul Mathew Mitchell E. Gross Mark N. Stein Alice Chen Kenneth J. Pienta June Escara-Wilke Gerald Doyle Mahmoud Al-Hawary Evan T. Keller Maha Hussain |
| Affiliation: | 1. Duke University, Durham, NC, USA 2. University of Michigan, Ann Arbor, MI, USA 3. University of California, San Francisco, CA, USA 4. The Cancer Institute of New Jersey, New Brunswick, NJ, USA 5. Tufts University School of Medicine, Boston, MA, USA 6. Cedars-Sinai Medical Center, Los Angeles, CA, USA 7. NCI/CTEP, Bethesda, MD, USA 8. Veridex, LLC, a Johnson & Johnson Company, Huntingdon Valley, PA, USA 9. University of Michigan Medical Center, 7314 Cancer Center, 1500 East Medical Center Drive, Ann Arbor, MI, 48109-5946, USA |
| Abstract: | |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |